Pharmaceutical Chemistry, School of Pharmacy, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa.
Eur J Med Chem. 2010 Oct;45(10):4458-66. doi: 10.1016/j.ejmech.2010.07.005. Epub 2010 Jul 31.
Monoamine oxidase (MAO) is an important drug target for the treatment of neurological disorders. A series of indole and benzofuran derivatives were synthesised and evaluated as inhibitors of the two MAO isoforms, MAO-A and MAO-B. In general, the derivatives were found to be selective MAO-B inhibitors with K(i) values in the nanoMolar (nM) to microMolar (microM) concentration range. The most potent MAO-B inhibitor, 3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide, exhibited a K(i) value of 0.03 microM and was 99 fold more selective for the B isoform. We conclude that these indole and benzofuran derivatives are promising reversible MAO-B inhibitors with a possible role in the treatment of neurodegenerative diseases such as Parkinson's disease (PD).
单胺氧化酶(MAO)是治疗神经紊乱的重要药物靶点。我们合成了一系列吲哚和苯并呋喃衍生物,并将其评估为两种 MAO 同型异构体,MAO-A 和 MAO-B 的抑制剂。一般来说,这些衍生物被发现是选择性 MAO-B 抑制剂,其 K(i) 值在纳摩尔(nM)到微摩尔(μM)浓度范围内。最有效的 MAO-B 抑制剂 3,4-二氯-N-(2-甲基-1H-吲哚-5-基)苯甲酰胺的 K(i) 值为 0.03 μM,对 B 同型的选择性高 99 倍。我们得出结论,这些吲哚和苯并呋喃衍生物是有前途的可逆 MAO-B 抑制剂,可能在治疗帕金森病(PD)等神经退行性疾病方面发挥作用。